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A B S T R A C T
Background
Cranberries have been used widely for several decades for the prevention and treatment of urinary tract infections (UTIs).
Objectives
To assess the effectiveness of cranberry products in preventing UTIs in susceptible populations.
Search strategy
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL in The Cochrane Library) and
the Internet. We contacted companies involved with the promotion and distribution of cranberry preparations and checked reference
lists of review articles and relevant studies.
Date of last search: January 2007.
Selection criteria
All randomised controlled trials (RCTs) or quasi-RCTs of cranberry products for the prevention of UTIs in all populations.
Data collection and analysis
Two authors independently assessed and extracted information. Information was collected on methods, participants, interventions
and outcomes (UTIs - symptomatic and asymptomatic, side effects, adherence to therapy). Relative risk (RR) were calculated where
appropriate, otherwise a narrative synthesis was undertaken. Quality was assessed using the Cochrane criteria.
Main results
Ten studies (n = 1049, five cross-over, five parallel group) were included. Cranberry/cranberry-lingonberry juice versus placebo, juice
or water was evaluated in seven studies, and cranberries tablets versus placebo in four studies (one study evaluated both juice and
tablets). Cranberry products significantly reduced the incidence of UTIs at 12 months (RR 0.65, 95% CI 0.46 to 0.90) compared
with placebo/control. Cranberry products were more effective reducing the incidence of UTIs in women with recurrent UTIs, than
elderly men and women or people requiring catheterisation. Six studies were not included in the meta-analyses due to methodological
issues or lack of available data. However, only one reported a significant result for the outcome of symptomatic UTIs. Side effects were
common in all studies, and dropouts/withdrawals in several of the studies were high.
Authors’ conclusions
There is some evidence that cranberry juice may decrease the number of symptomatic UTIs over a 12 month period, particularly for
women with recurrent UTIs. It’s effectiveness for other groups is less certain. The large number of dropouts/withdrawals indicates that
cranberry juice may not be acceptable over long periods of time. It is not clear what is the optimum dosage or method of administration
(e.g. juice, tablets or capsules). Further properly designed studies with relevant outcomes are needed.
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P L A I N L A N G U A G E S U M M A R Y
Cranberries for preventing urinary tract infections
Cranberries (usually as cranberry juice) have been used to try and prevent urinary tract infections (UTIs). Cranberries contain a
substance that can prevent bacteria from sticking on the walls of the bladder. This may help prevent bladder and other urinary tract
infections. This review identified 10 studies (1049 participants) comparing cranberry products with placebo, juice or water. There was
some evidence to show that cranberries (juice and capsules) can prevent recurrent infections in women. However, the evidence for
elderly men and women was less clear, and there is evidence that is not effective in people who need catheterisation. Many people in
the trials stopped drinking the juice, suggesting it may not be a popular intervention. In addition it is not clear how long cranberry
juice needs to be taken to be effective or what the required dose might be.
B A C K G R O U N D
The term urinary tract infection (UTI) refers to the presence of a
certain threshold number of bacteria in the urine (usually greater
than 100,000/mL). It consists of cystitis (bacteria in the bladder),
urethral syndrome and pyelonephritis (infection of the kidneys).
Lower UTIs involve the bladder, whereas upper UTIs also involve
the kidneys (pyelonephritis). Bacterial cystitis (also called acute
cystitis) can occur inmen and women and the signs and symptoms
include dysuria (pain on passing urine), frequency, cloudy urine,
occasionally haematuria (blood in the urine), and is often associ-
ated with pyuria (urine white cell count greater than 10,000/mL).
Urethral syndrome (frequency and dysuria syndrome) is used to
describe approximately 50%of women with these complaints who
have either nobacterial growth or counts less than100,000 colony-
forming units (cfu)/mL on repeated urine cultures. Pyelonephritis
most commonly occurs as a result of cystitis, particularly in the
presence of transient (occasional) or persistent backflow of urine
from the bladder into the ureters or kidney pelvis (vesicoureteric
reflux). Signs and symptoms include flank pain or back pain, fever,
chills with shaking, general ill feeling plus those symptoms of a
lower UTI. Acute pyelonephritis can be severe in the elderly, in
infants, and in people who are immunosuppressed (for example,
those with cancer or AIDS). Although most people who present
to the doctor or hospital have symptomatic UTIs, some can be
asymptomatic and only those who are at high risk of developing
further infections (pregnant women and the elderly) may require
treatment. Some people also have recurrent UTIs with an average
of two to three episodes/year (Roberts 1979; Wong 1984). Chil-
dren typically present with a high fever and systemic symptoms
such as lethargy (tiredness), vomiting and poor feeding.
Specific subpopulations at increased risk of developing a UTI.
These groups include infants, pregnant women, the elderly, pa-
tients with spinal cord injuries and/or catheters, patients with di-
abetes or multiple sclerosis, patients with acquired immunodefi-
ciency disease syndrome/human immunodeficiency virus, and pa-
tients with underlying urologic abnormalities (Foxman 2002). Al-
though UTIs can occur in both men and women, they are about
50 timesmore common in adult women than adultmen. Thismay
be because women have a shorter urethra that may allow bacte-
ria to ascend more easily into the bladder. Symptomatic infection
of the bladder (lower UTI) has been estimated to occur in up to
30% of women at some stage during their lives (Kelly 1977). Most
UTIs arise from the ’ascending’ route of infection. The first step is
colonisation of periurethral tissues with uropathogenic organisms,
followed by the passage of bacteria through the urethra. Infection
arises from bacterial proliferation (growth) within the otherwise
sterile urinary tract. In children, UTI occurs more commonly in
boys up to the age of six to 12 months, but overall occurs about
three times more often in girls (1% to 3% in boys, 3% to 7% in
girls) (Hellstrom 1991; Winberg 1974).
Cranberries (particularly in the form of cranberry juice) have been
used widely for several decades for the prevention and treatment
of UTIs. Cranberries comprise nearly 90% water, but also contain
various organic substances such as quinic acid,malic acid and citric
acid as well as glucose and fructose. Until recently, it was suggested
that the quinic acid caused large amounts of hippuric acid to be
excreted in the urine which then acted as an antibacterial agent
(Kinney 1979). Several studies, however, have shownno difference
in the levels, or only a transient (short lived) effect thus casting
some doubt on this theory (Kahn 1967; McLeod 1978). No defi-
nite mechanism of action has been established for cranberry in the
prevention or treatment of UTIs. However, the main suggestion
is that cranberries prevent bacteria (particularly Escherichia coli)
from adhering (sticking) to uroepithelial cells that line the wall of
the bladder (Schmidt 1988; Zafriri 1989). Without adhesion, E.
coli cannot infect the mucosal surface of the urinary tract. In vitro,
this adhesion is mediated by two components of cranberry; fruc-
tose, which inhibits adherence of type 1 (mannose specific) fim-
briated E. coli, (Foo 2000) and substances called proanthocyani-
dins, which inhibit the adherence of p-fimbriated (a-galactose-(1-
4) specific) E. coli (Zafriri 1989).
UTIs are one of the most common medical conditions requiring
outpatient treatment, and complications resulting from persistent
and repeated infections necessitate well over one million hospital
admissions annually in the USA (Patton 1991). The aim of this
review is to assess the effectiveness of cranberries in the prevention
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of UTIs in susceptible populations.
The treatment of UTIs with cranberries is evaluated in another
review by the same authors (Jepson 1998b).
O B J E C T I V E S
We wished to test the following hypotheses:
• Cranberry juice and other cranberry products are more effec-
tive than placebo/no treatment in the prevention of UTIs in
susceptible populations.
• Cranberry juice and other cranberry products are more effective
than any other treatment in the prevention of UTIs in suscep-
tible populations.
An attempt was also made to quantify the side effects of cranberry
juice and the findings were taken into account in the discussion
to determine the risk-benefit of the treatment.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
All randomised controlled trials (RCTs) of cranberry juice (or
derivatives) versus placebo, no treatment or any other treatment.
Quasi-RCTs (e.g. those studies which randomised participants by
date of birth, or case record number) were included, but the quality
of the studies was taken into account during the analysis and dis-
cussion. Both parallel group and cross-over design were included.
Types of participants
Inclusion criteria
Studies of susceptible men, women or children as defined below.
These categories were analysed separately.
• Participants with a history of recurrent lower UTIs (more than
two episodes in the previous 12 months).
• Elderly men and women.
• Participants needing intermittent catheterisation.
• Pregnant women.
• Participants with an in-dwelling catheter.
• Participants with an abnormality of the urinary tract.
Exclusion criteria
• Studies of the treatment of asymptomatic or symptomatic UTI
(these are analysed in a separate review by the same authors
Jepson 1998b).
• Studies of any urinary tract condition not caused by bacterial
infection (e.g. interstitial cystitis - a chronic inflammation of
the bladder wall).
Types of intervention
Cranberry juice or a cranberry product (e.g. cranberry capsules)
given for at least onemonth. If further studies become available for
review, the amount taken/day, concentrationof the juice/cranberry
product and length of treatment will be taken into account in
subgroup analyses.
Types of outcome measures
Primary outcome measure
• Number of UTIs in each group (confirmed by a catheter speci-
men of urine, mid stream specimen of urine (MSU) if possible,
or a ’clean catch’ specimen).
The ’gold standard’ bacteriological criteria for diagnosis of UTI
includes microbiological confirmation from a MSU (or similar
method) with greater than 100,000 bacterial cfu/mL, often asso-
ciated with pyuria (white cells in the urine). In some situations a
bacterial count < 100,000/mL is acceptable. For example, when a
supra-pubic bladder tap or a catheter urine specimen is obtained.
If further studies become available for review, the method of col-
lecting a specimen of urine, the causative organism (e.g. E. coli)
and the presence of mixed organisms in the urine (which signifies
contamination) will be subject to sensitivity analyses.
If further studies become available for review, this outcome will
also be subgrouped into rate of symptomatic lower UTIs, rate of
symptomatic upper UTIs (UTI plus fever) and rate of asymp-
tomatic UTIs. Symptomatic is defined as having one or more or
the following symptoms: dysuria, frequency, urgency.
Methods used to diagnose upper and lower UTIs will also be
subjected to sensitivity analysis if enough data is available.
Secondary outcome measures
• Adherence to therapy.
• Side effects.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Renal Group methods used in reviews.
Initial search
Relevant studies were obtained from the following sources (date
of last search January 2007):
1). The search strategy developed by the Cochrane Renal Group.
2). Cochrane Controlled Trials Register (CCTR) and CENTRAL
(issue 1, The Cochrane Library 2007)
3). Registry of randomised trials for the Cochrane Collaboration
Field in Complementary Medicine.
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4). Companies involved with the promotion and distribution of
cranberry preparations were approached and asked to provide
information on both published and unpublished studies.
5). Electronic databases including PsycLit, LILACS, CINAHL,
MEDLINE, EMBASE, Biological Abstracts, Current Contents.
These databases were searched using the following terms*:
1. (beverages.sh. or cranberr$.ti,ab or fruit adj5 beverage$.ti,ab.
or fruit adj5 drink$.ti,ab. or fruit adj5 juice$ or vaccinium
macrocarpon.ti,ab. or vaccinium oxycoccus.ti,ab. or vaccinium
vitis-idaea.ti,ab.)
2. (UTIs.sh. or cystitis.sh. or bacteriuria.sh. or pyelonephritis.sh.
or UTI$.ti,ab. or urinary adj5 infection$.ti,ab. or bacter$.ti,ab.
or pyelonephrit$.ti,ab. or cystitis.ti,ab.)
3. 1 and 2
(* this is the MEDLINE search strategy. The EMBASE search
expressions are slightly different but the search terms were the
same, except that the term urogenital tract infections was also
searched on as a subject heading.)
6). The following terms were searched to identify non-English
language studies:
• Danish - (Tranebaersaft.ti,ab. or tranebaer.ti,ab. or
orkaempetranebaer.ti,ab. or store tranebaer.ti,ab. or
cranberry.ti,ab.) and (urinvejsinfektion.ti,ab. or cystitis.ti,ab.
or blaerebetaendelse.ti,ab. or pyelonephritis.ti,ab. or
pyelonefrit.ti,ab.)
• Dutch - (veenbes.ti,ab. or lepeltjeheide.ti,ab. or
lepeltjesheide.ti,ab. or Amerikaanse veenbes.ti,ab. or
cranberry.ti,ab.) and (cystitis.ti,ab. or catarrhus.ti,ab.
or vesicalis.ti,ab. or blaasontsteking.ti,ab. or
urineweginfectie.ti,ab. or pyelonephritis.ti,ab. or
nephropyelitis.ti,ab.)
• French - (canneberges ronce d’Amerique.ti,ab. or
cranberry.ti,ab. or cranberrie.ti,ab.) and (cystite.ti,ab. or
infection urinaire.ti,ab. or pyélonéphrite.ti,ab.)
• German - (moosbeere.ti,ab or kranbeere.ti,ab.) and
(zystitis.ti,ab. or cystitis.ti,ab. or harnwegsinfektion.ti,ab. or
harninfekt.ti,ab. or pyelonephritis.ti,ab.)
• Italian - (vaccinium oxycoccus.ti,ab. or ossicocco
palustro.ti,ab.) and (cistite.ti,ab. or infezione del tratto
urinario.ti,ab or infezione urinaria.ti,ab. or infezione delle vie
urinarie.ti,ab. or pielonefrite.ti,ab. or nefropielite.ti,ab.)
• Portuguese - (cranberry.ti,ab. or oxicoco$.ti,ab. or vaccinium
oxycoccos.ti,ab. or oxycoccus palustris) and (cistite.ti,ab. or
pielonefrite.ti,ab.)
• Spanish - (arandano agrio.ti,ab or arandano americano.ti,ab.)
and (cistitis.ti,ab. or infección urinaria.ti,ab or
pielonefritis.ti,ab.)
7). The Internet was searched using the terms listed in 3) and 4).
8). Reference lists of review articles and relevant studies were
searched.
9). Conference abstracts from The Proceedings of the Urological
Association (1990-1998), and The Journal of the American
Geriatrics Society (1990 -1998) were searched for relevant
studies.
10). The National Research Register was searched for studies
currently underway.
Review update
For this update the Cochrane Renal Group’s specialised register
and CENTRAL was searched. CENTRAL and the Renal
Group’s specialised register contain the handsearched results of
conference proceedings from general and speciality meetings.
This is an ongoing activity across the Cochrane Collaboration
and is both retrospective and prospective (Master List 2007).
Please refer to The Cochrane Renal Review Group’s Module
in The Cochrane Library for the complete list of nephrology
conference proceedings searched.
Date of most recent search: January 2007
M E T H O D S O F T H E R E V I E W
The search strategy described previously was employed to obtain
titles and, where possible, abstracts of studies that were potentially
relevant to the review. The titles and abstracts were screened by
RJ, who discarded studies that were clearly ineligible but aimed
to be overly inclusive rather than risk losing relevant studies. Two
authors independently assessed, using full copies of the papers,
whether the studies met the inclusion criteria, with disagreements
resolved by discussion. Further information was sought from the
authors of those papers which contained insufficient information
to make a decision about eligibility.
The quality of all studies which were deemed eligible for the
review were then assessed independently by two authors, with
discrepancies resolved by discussion. The quality of allocation
concealment was graded as either (A) adequate, (B) unclear, or (C)
inadequate, following the detailed descriptions of these categories
provided by the Cochrane Collaboration. It was intended to use
this grading in investigation of any heterogeneity and in sensitivity
analyses. Other aspects of study quality assessed included the
extent of blinding, whether groups were comparable at baseline,
the extent of losses to follow-up, non-participation, whether the
outcome assessment was standardised, and whether an “intention-
to-treat” analysis was undertaken. This information is presented
in a table describing the included studies and the section on
methodological quality, and provided a context for discussing
the reliability of the results. Summary tables are provided in the
additional tables (Table 01 - Characteristics of studies;Table 02 -
Study design and quality of reporting).
Two authors independently extracted information using specially
designed data extraction forms. For each included study,
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information was collected regarding the location of the study,
methods of the study (as per quality assessment checklist),
the participants (sex, age, eligibility criteria), the nature of
the interventions, and data relating to the outcomes specified
previously. Where possible, missing data (including side effects)
were sought from the authors. Discrepancies in the data extraction
were resolved via discussion.
Studies with either parallel group or cross-over design were
included in the review. For cross-over studies, only the period
before the cross-over is able to be synthesised inRevMan.However,
this data were not available for any of the studies, so end of study
data were reported descriptively (Table 03 - Asymptomatic UTIs
(bacteraemia); Table 04 - Symptomatic UTIs). Relative risk (RR)
were used as the measure of effect for dichotomous outcomes,
using a random effects model. Studies were sub-grouped by
population type (e.g. the elderly, young women). If enough data
becomes available in the future, heterogeneity in the data will
be noted and cautiously explored using previously identified
characteristics of the studies, particularly assessments of quality.
Sensitivity analyses will be undertaken to examine the stability
of the results in relation to a number of factors including study
quality, the source of the data (published or unpublished), the
method used for confirming the presence of bacteria in the urine
(e.g. catheter specimen of urine or midstream specimen of urine),
the causative organism (e.g. E. coli) and the method of diagnosing
upper or lower UTI. Where continuous scales of measurement
are used to assess the effects of treatment, these data will be
analysed in continuous form using the mean difference (WMD).
If different scales are used in different studies the results will be
standardised and then combined using the standardised mean
difference (SMD).
If further studies become available for inclusion in the review, the
groups of susceptible populations described previously (see under
types of participants) will be analysed separately with the following
subgroups:
• Dosage (amount and concentration).
• Frequency and duration of treatment..
• In elderly women, number on hormone replacement therapy
and/or topical vaginal oestradiol (these have been shown to
reduce UTIs).
Where possible, we sought data from within studies where these
comparisons have been made, rather than making comparisons
across studies.
D E S C R I P T I O N O F S T U D I E S
Ten studies (1049 participants) were included (see Table of in-
cluded studies for more details). Of these, two were only published
as letters, and no additional data were received from the authors
(Haverkorn 1994; Walker 1997). Eight studies had one interven-
tion arm and one control arm, and evaluated the effectiveness of ei-
ther cranberry juice/cocktail (Avorn 1994; Foda 1995; Haverkorn
1994; McMurdo 2005; Schlager 1999) or cranberry capsules (Lin-
senmeyer 2004; Waites 2004; Walker 1997). A further two studies
had two intervention arms and a control arm (Kontiokari 2001;
Stothers 2002). Kontiokari 2001 randomised participants to ei-
ther cranberry-lingonberry juice, lactobacillus GG drink or no in-
tervention. Stothers 2002 randomised participants to cranberry
juice, cranberry tablets or placebo juice.
Two studieswere excludedbecause although theywere randomised
and compared cranberry juice with placebo in susceptible popu-
lations, they did not meet other inclusion criteria (Jackson 1997;
Schultz 1984) (see Table of excluded studies for more details).
Types of participants
a) Participants with a history of recurrent lower UTIs or young
women with an uncomplicated UTI
Two studies included women with recurrent UTIs (Stothers 2002;
Walker 1997) and one study recruited women with a current UTI
(Kontiokari 2001). The definition that the studies used for re-
current UTIs were either four UTIs during the past year or at
least one during the previous three months (Walker 1997) or
two symptomatic, single-organism, culture positive UTIs in the
previous calendar year (Stothers 2002). Two were parallel group
RCTs which were undertaken in Finland (Kontiokari 2001) and
Canada (Stothers 2002). One of these studies had to be stopped
prematurely (after six months) because the cranberry juice sup-
plier stopped producing the juice (Kontiokari 2001). The third
study was a small cross-over study undertaken in America (Walker
1997). Nineteen women were randomised to either cranberry cap-
sules or placebo, but only 10 completed the study and were in-
cluded in the final analysis.
b) Elderly men and women
Three studies evaluated cranberry juice for the prevention of UTIs
in elderly populations (Avorn 1994; Haverkorn 1994; McMurdo
2005). The largest and best quality study was a study undertaken
in Scotland (McMurdo 2005). Three hundred and sixty hospital
patients aged 60 years or over were randomised to daily ingestion
of 300 mL of cranberry juice or matching placebo beverage using
a parallel group design. Avorn 1994 was a quasi-RCT of elderly
women in America and this study used a parallel group design and
randomised participants to either cranberry juice or placebo juice.
Although 192womenwere initially randomised to treatment, only
153 provided enough data to be included in the final analysis.
The third study was undertaken in The Netherlands (Haverkorn
1994) and used a cross-over design and included both men and
women. Thirty eight people were randomised to either cranberry
juice or water, but only 17 completed treatment and only seven
were included in the final analysis.
c) Participants needing catheterisation (intermittent or in-
dwelling)
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Four studies evaluated the effect of cranberry products in people
needing either indwelling catheters or intermittent catheterisation.
All the participants in the studies had neuropathic bladders. Two
studies evaluated the effectiveness of cranberry juice in children
who had a paediatric neuropathic bladder and were managed by
clean intermittent catheterisation (Foda 1995; Schlager 1999).
Both were cross-over studies and included 40 children, and 15
children respectively.
A further two studies evaluated the effectiveness of cranberry cap-
sules/tablets versus placebo in people who had spinal cord injuries
(Linsenmeyer 2004; Waites 2004). Linsenmeyer 2004 was a cross-
over studywhich randomised 37 patients and analysed results from
21. Waites 2004 was a parallel group study which randomised 74
patients and analysed results from 48.
Dosage, concentration and duration of the cranberry inter-
vention
Of the seven studies which evaluated the effectiveness of cranberry
juice, four studies used placebo juice in the control arm (Avorn
1994; McMurdo 2005; Schlager 1999; Stothers 2002), one study
used no intervention ( Kontiokari 2001) and the other two studies
used water (Foda 1995; Haverkorn 1994). One study made the
participants buy their own cranberry juice (Foda 1995) and the
others provided it free of charge. For adults, the amount given
ranged from 30 mL/d (Haverkorn 1994) to 300 mL/d (Avorn
1994; McMurdo 2005). In children it was 15 mL/kg (Foda 1995)
and 300 mL/d (Schlager 1999). The rationale behind the amount
and concentrate of cranberry juice given to participants was not
mentioned in any of the studies, and onlyMcMurdo 2005 detailed
the amount of active component (a proanthocyanidin concentra-
tion of 11.175 µg/g - dry solids basis). Of the four studies which
evaluated the effectiveness of cranberry capsules, two gave partic-
ipants capsules containing 400 mg of cranberry solids (Linsen-
meyer 2004; Walker 1997), Waites 2004 gave capsules containing
2 g concentrated cranberry juice and Stothers 2002 gave partici-
pants cranberry tablets containing 1:30 parts of concentrated juice
twice/day.
Outcomes
In all of the studies, either symptomatic or asymptomatic UTI was
one of the outcome measures.
M E T H O D O L O G I C A L Q U A L I T Y
Allocation concealment
In general, the methodological quality of the studies was good.
Four used adequate concealment of allocation (Kontiokari 2001;
McMurdo 2005; Schlager 1999; Stothers 2002). Four did not state
the method of randomisation (Foda 1995; Linsenmeyer 2004;
Waites 2004; Walker 1997) and were graded B (unclear). Avorn
1994 and Haverkorn 1994 used a quasi-randomised method of
allocated and were graded C (inadequate).
Blinding and study design
Five studies used a cross-over design (Foda 1995;Haverkorn 1994;
Linsenmeyer 2004; Schlager 1999; Walker 1997) and five used a
parallel group design (Avorn 1994; Kontiokari 2001; McMurdo
2005; Stothers 2002; Waites 2004). Seven of the studies were
double-blind (Avorn 1994; Linsenmeyer 2004; McMurdo 2005;
Schlager 1999; Stothers 2002;Waites 2004;Walker 1997), inFoda
1995 the investigator was blind but not the assessor and there was
no blinding at all in Haverkorn 1994 and Kontiokari 2001.
Withdrawals, losses to follow-up and intention-to-treat
The dropout rate in all studies varied considerably. Two studies
reported no drop-outs (Schlager 1999; Stothers 2002), however
adherence with treatment was reported as being less than 80% in
5/12months in Stothers 2002. In the other studies the drop-out or
withdrawal rates were 8% (Kontiokari 2001), 20% (Avorn 1994),
30% (McMurdo 2005), 35% (Waites 2004), 43% (Linsenmeyer
2004), 47% (Foda 1995; Walker 1997) and 55% (Haverkorn
1994). Only two of the studies used an intention-to-treat analysis
(Kontiokari 2001; McMurdo 2005).
In Avorn 1994 some of the baseline characteristics of the partic-
ipants were markedly different in the cranberry and the placebo
group. In particular, the rate of UTIs in the previous six months
in the placebo group was over three times that of the cranberry
juice group, and double for over 12months. Two letters, published
in JAMA, commented on these differences and inferred that the
randomisation and/or blinding scheme had failed (Hopkins 1994;
Katz 1994).
All first authors were contacted for more data if necessary. Three
authors replied (Kontiokari 2001; Stothers 2002; Walker 1997)
but no additional information was obtained from one of these
communications (Walker 1997).
R E S U L T S
Meta-analysis was performed using the data from four studies
(Kontiokari 2001; McMurdo 2005; Stothers 2002; Waites 2004).
Data from the cross-over studies were not available from the pre-
crossover period (Haverkorn 1994; Foda 1995; Haverkorn 1994;
Linsenmeyer 2004; Schlager 1999; Walker 1997), and data were
unclear in the quasi-RCT (Avorn 1994). The results from the
cross-over studies and the quasi-RCT are reported in the addi-
tional tables, and also descriptively in the text.
In summary, meta-analysis of the results of the four RCTs found
that cranberry products significantly reduced the incidence of
UTIs at twelve months (analysis 01.01: RR 0.66, 95% CI 0.47 to
0.92) compared with placebo/control. Within these studies, cran-
berry products were more effective reducing the incidence of UTIs
in women with recurrent UTIs, than elderly men and women or
people requiring catheterisation (although no direct comparison
was made). For the five studies not included in the meta-analyses,
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only Walker 1997 reported a significant result for the outcome
of symptomatic UTIs (see additional Table 03 and Table 04 for
more information). Four of these studies measured the outcome
of asymptomatic UTIs (bacteriuria with or without pyuria), but
only Avorn 1994 reported a significant result. Side effects were
common in all studies, and the number of dropouts/withdrawals
in several studies was high.
Participants with a history of recurrent lower UTIs or women
with a UTI
i) Symptomatic UTIs
Data were available for meta-analyses from two RCTs (Kontiokari
2001; Stothers 2002). One gave 7.5 g cranberry concentrate daily
(in 50 mL) (Kontiokari 2001), the other gave 1:30 concentrate
given either in 250 mL juice or in tablet form (Stothers 2002).
When data from cranberry products (capsules and juice) were
combined and compared with placebo/control, the RR was 0.61
(analysis 01.01.01: 95% CI:0.40 to 0.91).
Kontiokari 2001 reported that at six months, eight (16%) women
in the cranberry group, 19 (39%) in the lactobacillus group, and
18 (36%) in the control group had at least one recurrence. In
the third study (Walker 1997), there were 21 incidents of UTIs
amongst the 10 people who completed the study. Six were in the
treatment group, and 15 were in the placebo group (P < 0.005).
ii) Asymptomatic UTIs (bacteruria)
This was not reported as an outcome in any of the three studies.
iii) Side effects and adherence to therapy
The reason for the nine withdrawals in Walker 1997 were: preg-
nancy, unrelated infections requiring antibiotic therapy, and mov-
ing from the area. No participants reported side effects. In Kon-
tiokari 2001, 13 women dropped out, mainly because of moving
away. In Stothers 2002 compliance during the 12 months was less
for cranberry juice than for the placebo and tablet groups, with
compliance dropping below 80% during 5/12 months. Two par-
ticipants in the cranberry juice group dropped out due to symp-
toms of reflux and other problems reported included mild nausea
and frequency of bowel movements (in the tablet group). Partici-
pants in the placebo group also complained of headache and mild
nausea.
Elderly men and women
i) Symptomatic UTIs
InMcMurdo 2005 21/376 (5.6%) participants developed a symp-
tomatic UTI, 14/189 in the placebo group and 7/187 in the cran-
berry juice group. These between-group differences were not sig-
nificant (analysis 01.01.02: RR 0.51, 95%CI 0.21 to 1.22). There
were significantly fewer infections with E. coli in the cranberry
group (13 versus 4) with the authors suggesting that the result
should be interpreted with caution as it was a secondary outcome.
Avorn 1994 reported 4% (20/473) of the urine samples in the
treatment group and 7% (37/498) in the placebo group had bac-
teriuria and pyuria concurrent with the subjects reporting urinary
tract symptoms (P = not significant). These figures, however, ap-
pear to include the baseline urine samples (i.e. before the par-
ticipants began drinking either cranberry juice or placebo juice).
Haverkorn 1994 gave no details about symptomatic UTIs.
ii) Asymptomatic UTIs (bacteruria)
From the 1993 abstract of Avorn 1994 subjects randomised to the
cranberry juice were 58% (author’s OR, 0.42) less likely than con-
trols to have bacteriuria with pyuria (P = 0.004) using 971 samples.
These results reappeared in the 1994 report but readers are led to
believe that the results are based upon 818 urine samples. It was
unclear whether the denominator was 971 urine samples (which
would appear to include baseline measurements prior to being
given either cranberry juice or placebo juice) or 818 urine samples.
Of the 17 people who completed the study by Haverkorn 1994,
three had a UTI for the whole study period, seven had no UTI
during the study period and seven had one or more episodes. In
these seven, there were fewer occurrences of UTI when cranberry
juice was being taken. The data from 17 people were not analysed
together and no further data has been provided. The study only
analysed the data from those participants who had a new UTI
(7/17 who completed the study).
iii) Side effects and adherence to therapy
InMcMurdo 2005 themedian [IQR] adherence from amaximum
of 300 mL/day was good at 300 [44] mL for the placebo beverage
and 300 [28] mL for the cranberry juice (P = 0.208). Only 13
adverse events occurred and all resulted in withdrawal from the
study. The six in the placebo group comprised two deaths and
four episodes of gastrointestinal upset. The seven in the cranberry
group comprised three deaths, two episodes of gastrointestinal
upset, one episode of skin redness and itching, and one elevated
blood glucose level in a known diabetic patient. Adherence data
weremissing for 11/376 (2.9%) participants, five from the placebo
group and six from the cranberry juice group.
No data on side effects, or adherence to therapy were reported in
other two studies apart from the number of withdrawals/dropouts.
In Avorn 1994, 20% (39/193) of the participants withdrew from
the study without providing any urine samples after baseline. No
reasons for withdrawal were reported. Of the 153 who were in-
cluded in the analysis, 21% (32) did not complete the full six
months; 17% (12/72) received cranberry juice, and 25% (20/81)
received placebo. Thus, out of 192 randomised, 37% (72) did not
finish the study. In Haverkorn 1994, 55% (21/38) of those ran-
domised did not complete the study.
iv) Antibiotic use
In McMurdo 2005, a total of 35/189 (19%) of participants in
the placebo group were prescribed antibiotics for any indication
during the period of observation, compared to 32/187 (17%) of
the cranberry juice group (P = 0.721). The median (range) dura-
tion of antibiotic treatment was 7 (1-19) days and 7 (1-15) days
respectively.
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Participants needing catheterisation (intermittent or in-
dwelling)
i) Symptomatic UTIs
There was no clinical nor statistical difference in the number of
symptomatic UTIs observed in either the cranberry or placebo
groups (Foda 1995; Linsenmeyer 2004; Schlager 1999; Waites
2004). Relative risks were only able to be calculated for Waites
2004, and this was not significant (analysis 01.01.03: RR 1.06,
95% CI 0.51 to 2.21).
ii) Asymptomatic UTIs (bacteruria)
In Foda 1995, the percentage ofmonthswith a positive culture and
no UTI symptoms was 24.1% (27/112) in the cranberry group
and 17.1% (20/117) in the water group (P = not significant).
In Schlager 1999, the percentage of urine cultures in both the
treatment and control group were identical (75%). In the other
three studies, no statistical differences were found between the
intervention and control group.
iii) Side effects and adherence to therapy
In Foda 1995, there were 19 withdrawals/dropouts from the study,
89% (17/19) whilst on cranberry. Of these 17 withdrawals, the
reasons 12 gave were directly due to cranberry. The reasons given
were taste (9), caloric load (2) and cost (1). The other five dropouts
were too busy (2), no reason (2) and non-urologic death (1). In the
water group there were two dropouts, but neither gave a reason.
No drop-outs or side effects were reported in Schlager 1999.
Cost effectiveness
Stothers 2002 reported on the cost effectiveness of the interven-
tion. The mean annual cost of prophylaxis was CAD$624 and
CAD$1400 for cranberry tablets and juice respectively. Cost sav-
ings were greatest when patients experiencedmore than two symp-
tomatic UTIs/year (assuming three days of antibiotic coverage)
and had more than two days of missed work or required pro-
tective undergarments for urgency incontinence. Total antibiotic
consumption was less annually in both treatment groups com-
pared with placebo. Cost effectiveness ratios demonstrated cran-
berry tablets were twice as cost effective as organic juice for pre-
vention.
D I S C U S S I O N
There is some evidence from the studies that cranberry juice and
derivatives might be effective in preventing the re-occurrence of
UTIs. Post-hoc analysis of the data (both in the meta-analysis and
the study data) suggest that cranberry products may be effective
in women with recurrent UTIs and the elderly, but do not appear
to be effective in people with neuropathic bladders. For example,
the two good quality RCTs which did find an effect were both in
women with recurrent UTIs. The largest RCT to have examined
the effect of cranberry juice ingestion on symptomatic UTI rates
(and the only one to have participants of both sexes) had an ob-
served symptomatic infection rate which was considerably lower
than anticipated. This resulted in the study being accordingly un-
derpowered (McMurdo 2005).
The five cross-over studies (Foda 1995; Haverkorn 1994; Linsen-
meyer 2004; Schlager 1999;Walker 1997) were very small, and the
number of dropouts in three were high. Furthermore, it is debat-
able whether the data from the quasi-RCT (Avorn 1994), which
reported that cranberry juice was effective in reducing the number
of asymptomatic UTIs, were reliable on two main counts. Firstly,
only a quasi-randomisation method was used and the differences
in the baseline characteristics between the two groups suggests that
the randomisation and/or blinding scheme failed. Secondly it is
possible that the analyses reported included the baseline measure-
ments in the denominator (i.e. before the participants started on
either the cranberry juice or the placebo juice).
What is of most interest to the clinician and consumer is whether
cranberry juice is effective in preventing symptomatic UTIs. How-
ever, the main outcome in two of the studies was the bacterio-
logical (not clinical) diagnosis of UTI (Avorn 1994; Haverkorn
1994). In the largest study (Avorn 1994), the introduction stated
that, ’much bacteriuria in this age group (elderly) is asymptomatic
and does not require treatment...’ Thus, even if cranberry juice is
effective in preventing asymptomatic UTIs, it is a condition which
does not normally need treating in certain populations.
None of the studies of cranberry juice justified the dosage of cran-
berries given to participants. In addition, there was no standard-
isation of the description of the dosage (i.e. concentration) given
which made comparison difficult. For example, some studies de-
scribed the amount in millilitres, without stating the concentra-
tion. Participants in Avorn 1994 received 10 times more cran-
berry juice than Haverkorn 1994 (300 mL versus 30 mL). The
concentration of cranberries in the Avorn 1994 was 30% but the
concentration of the juice used in Haverkorn 1994 was not stated.
It could be possible that the concentration of cranberries was the
same in both studies, however the amount of juice given differed.
Generally the chemical composition of available cranberry prod-
ucts is not standardised, and the bioequivalence between the juice
and capsules/tablets is not clear. Furthermore, none of the studies
justified their duration. UTIs often occur in clusters with long pe-
riods (several months) where patients are symptom free (Stapleton
1997). Thus studies may need to cover much longer time periods
to take into account the natural course of the illness.
The number of withdrawals in some of the studies was high (20%
to 55%). This could indicate that cranberry juice is not an ac-
ceptable therapy taken over a long period of time. Children in
particular cited taste as the main reason for withdrawal (Foda
1995). Furthermore, the cost of consuming large amounts of cran-
berry juice may limit acceptance in the general population. The
studies of cranberry extract (Walker 1997) and cranberry capsules
(Stothers 2002) may have overcome some of these issues of com-
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pliance and cost. Withdrawals from the two studies of cranberry
capsules/tablets in people with neuropathic bladders (Linsenmeyer
2004; Waites 2004) were high (> 40%), but reasons for the with-
drawals were not related to taste.
Two studies of cranberry juice for UTIs were excluded from this
review. Jackson 1997 was excluded because the main outcome of
interest was urinary pH. Outcomes relevant to this review were
not evaluated. Schultz 1984 was excluded because people were
only randomised to 20 days of treatment. The inclusion criteria
for this review was a minimum length of treatment of one month.
Furthermore, number of UTIs was not a primary outcome and
only descriptively reported.
No published studies have been undertaken that compare cran-
berry with established interventions (e.g. antibacterials) for pre-
venting UTIs. Theoretically, using cranberry instead of antibac-
terials might reduce the risk for the development of antibacterial-
resistant organisms (Howell 2002) but there is currently no evi-
dence to confirm this.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Overall, the evidence from four RCTs indicates that cranberry
products can be effective in reducing UTIs. However, it may only
be effective in certain sub-populations. From the results of twowell
conducted RCTs there is some evidence to recommend cranberry
juice for the prevention of UTIs in women with symptomatic
UTIs. The evidence is inconclusive as to whether it is effective in
older people (bothmen andwomen), and current evidence suggest
that it is not effective in people with a neuropathic bladder. In
addition, the large number of dropouts/withdrawals from some of
the studies, indicates that cranberry juice may not be acceptable
over long periods of time. Furthermore, there is no clear evidence
as to the amount and concentration that needs to be consumed,
and the length of time for the intervention to be most effective.
Implications for research
Large, properly randomised, parallel group, placebo controlled,
double blind studies are needed to determine the effectiveness of
cranberries for the prevention of UTIs in susceptible populations.
The study period needs to be longer than six months to take into
account the natural course of the illness, since UTIs often occur in
clusters with long periods (several months) during which patients
are symptom free. Furthermore, the dosage and concentration of
the cranberry juice/product to be given should be determined sci-
entifically. Outcomes should include the number of symptomatic
and asymptomatic UTIs, side effects and adherence to therapy.
The large number of dropouts/withdrawals in the cranberry juice
studies included in this review indicates that drinking consider-
able amounts of cranberry juice over a long period may not be
acceptable. Further studies of cranberry capsules/tablets or other
cranberry products, therefore, are also needed.
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T A B L E S
Characteristics of included studies
Study Avorn 1994
Methods Country: USA
Method of randomisation/allocation: Institutional ID number or telephone number (quasi randomised).
Recruitment: Recruited from a long-term care facility for the elderly, and 9 housing complexes for the elderly.
Blinding: Double blind (participants and investigators).
Number of centres: One
Design: Placebo controlled, parallel group
Power calculation: Yes
Number of patients randomised: 192
Number of patients analysed: 153
Losses to follow-up/withdrawals: 39
Exclusions post randomisation: None
Intention-to-treat analysis: No
Source of funding: Research grant from Ocean Spray Cranberries, Inc.
Participants INCLUSION CRITERIA
Not clearly stated, but participants had to be willing to ingest at least 300 mL of cranberry juice daily for a
6 month period.
Number: 192 elderly women
Age: mean 78.5 years
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Characteristics of included studies (Continued )
EXCLUSION CRITERIA
Terminal disease or severe dementia; only women were studied.
Interventions INTERVENTION
300 mL cranberry juice cocktail/day (30% cranberry concentrate).
CONTROL
Placebo beverage that looked and tasted similar but contained no cranberry juice.
DURATION: 6 months
Outcomes 1. Presence of bacteriuria (bacteria in the urine greater or equal to 100,000/mL) with the presence of pyuria
(white cells in the urine).
2. Presence of bacteriuria.
3. Presence of bacteriuria with the presence of pyuria plus symptoms of a UTI.
Notes A total of 192 subjects were enrolled in the study.
Data were presented for 153 subjects who provided a baseline urine sample and at least one additional sample
after randomisation.
METHOD OF OBTAINING URINE SAMPLE
Mid-stream clean-voided.
DEFINITION OF BACTERIURIA
Organisms numbering greater or equal to 100,000/mL regardless of organism.
DEFINITION OF PYURIA: NS
Allocation concealment C – Inadequate
Study Foda 1995
Methods Country: Canada
Method of randomisation/allocation: NS
Blinding: Single blind (physician)
Number of centres: One
Source of patients: Clinic
Design: Cross-over
Power calculation: No
Number of patients randomised: 40
Number of patients analysed: 21
Losses to follow-up/withdrawals: 19
Exclusions post randomisation: None
Intention-to-treat analysis: No
Source of funding: NS
Participants INCLUSION CRITERIA
Neuropathic bladder and managed by clean intermittent catheterisation.
Outpatients’ residence at a distance not exceeding 150 km from the Children’s Hospital of Eastern Ontario.
No significant medical conditions.
Number: 40 children
Age: 1.4 to 18 years (mean 9.35) .
EXCLUSION CRITERIA: NS
Interventions INTERVENTION
Cranberry cocktail 15 mL/kg/d (30% cranberry concentrate)
CONTROL
Water
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Characteristics of included studies (Continued )
DURATION: 6 months cranberry juice, 6 months water
Outcomes 1. Number of months of positive cultures plus a symptomatic UTI.
2. Number of months of positive cultures plus an asymptomatic UTI.
3. Side effects and compliance.
Notes METHOD OF COLLECTING URINE
Sterile catheter urine samples.
DEFINITION OF BACTERIURIA
Greater than or equal to 100,000 cfu/L of a pathogenic organism after 24 hours incubation.
Any growth in a symptomatic patient was considered significant.
Allocation concealment B – Unclear
Study Haverkorn 1994
Methods Country: The Netherlands
Source of participants: Hospital
Method of allocation/randomisation: Date of birth (quasi randomised)
Blinding: No
Number of centres: One
Design: Cross-over
Power calculation: No
Number of patients randomised: 38
Number of patients analysed: 7
Losses to follow-up/withdrawals: 22
Exclusions post randomisation: None
Intention-to-treat analysis: No
Source of funding: NS
Participants INCLUSION CRITERIA: NS
Number: 38 participants
Age: mean 81 years
Sex (M/F): 9//29
EXCLUSION CRITERIA: NS
Interventions INTERVENTION
30 mL cranberry juice/day mixed with water.
Concentration: NS.
CONTROL
Water (same volume as intervention).
DURATION
4 weeks active treatment (8 weeks total).
Outcomes 1. Bacteriuria.
Notes Method of obtaining urine sample: NS
DEFINITION OF BACTERIURIA
>/= 100,000 cfu of one of the Enterobacteriaceae/mL of urine.
Allocation concealment C – Inadequate
Study Kontiokari 2001
Methods Country: Finland
Source of participants: Finnish student health service
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Characteristics of included studies (Continued )
Method of allocation/randomisation: Random number tables and sealed opaque envelopes (see footnote 1).
Blinding: No
Number of centres: One
Design: Parallel group
Power calculation: Yes, but recruitment stopped before appropriate number recruited.
Number of patients randomised: 150
Number of patients analysed: 150
Losses to follow-up/withdrawals: 13
Exclusions post randomisation: None
Intention-to-treat analysis: Yes
Source of funding: Emil Aaltonen, Juho Vainio, and Alma and K A Snellman Foundations
Participants INCLUSION CRITERIA
Women who had a UTI caused by E. coli (105 cfu/mL in clean voided midstream urine) and were not taking
antimicrobial prophylaxis.
Number: 150 women
Age: mean age in the three groups was 29-32 years
EXCLUSION CRITERIA: NS
Interventions INTERVENTION
50 mL of cranberry-lingonberry juice concentrate (Maija, Marli, Finland) a day.
The cranberry-lingonberry juice contained 7.5 g cranberry concentrate and 1.7 g lingonberry concentrate in
50 mL of water with no added sugars OR 100 mL of Lactobacillus GG drink (Gefilus, Valio, Finland) five
days a week.
CONTROL
No intervention
DURATION
6 months cranberry juice, 12 months lactobacillus.
Outcomes 1. First recurrence of symptomatic UTI.
Notes METHOD OF COLLECTION URINE
Clean voided midstream urine specimen.
DEFINITION OF BACTERIURIA
Bacterial growth 10(5) cfu/mL.
Recruitment had to be stopped prematurely because the cranberry juice supplier stopped producing the juice.
A total of 150 women gave their informed consent and were randomly allocated into three groups, 50 in
each. One subject in the lactobacillus group who was taking post coital antimicrobials was excluded from
the analysis.
Allocation concealment A – Adequate
Study Linsenmeyer 2004
Methods Country: USA
Source of participants: Patients presenting to outpatient urology rehabilitation clinic.
Method of allocation/randomisation: NS
Blinding: Double blind
Number of centres: One
Design: Cross-over
Power calculation: NS
Number of patients randomised: 37
Number of patients analysed: 21
Losses to follow-up/withdrawals: 16
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Characteristics of included studies (Continued )
Exclusions post randomisation: None
Intention to treat analysis: No
Source of funding: Eastern Paralyzed Veterans Association.
Participants INCLUSION AND EXCLUSION CRITERIA: NS.
21 individuals with neurogenic bladders secondary to spinal cord injury.
Interventions INTERVENTION
standardised 400 mg cranberry tablets.
CONTROL
Placebo
DURATION
9 weeks (4 weeks on each, plus one week wash out).
Outcomes 1. Urinary bacterial counts and white blood cell (WBC) counts and the combination of bacterial and WBC
counts.
Notes METHOD OF COLLECTING URINE SAMPLE
CSU or MSU
DEFINITION OF BACTERIURIA
>/= 10,000/mL for a MSU; > 100 cfu/mL for a CSU
Allocation concealment B – Unclear
Study McMurdo 2005
Methods Country: Scotland
Method of allocation/randomisation: Computer-generated random numbers program. Allocation by sealed
envelopes in numbered sequence
Blinding: Double blind
Number of centres: One
Design: Parallel group
Power calculation: Yes
Number of patients randomised: 376
Number of patients analysed: 376
Losses to follow-up/withdrawals: 115
Exclusions post randomisation: None
Intention-to-treat analysis: Yes
Source of funding: Chief Scientist Office at the Scottish Executive Department of Health. The cranberry
juice and matching placebo were supplied by Ocean Spray Cranberries, Inc.
Participants Number: 376 older patients in hospital.
Age: 60 years or over admitted to either acute medicine for the elderly assessment or rehabilitation units for
elderly people.
EXCLUSION CRITERIA
Mental State Questionnaire (MSQ) score <5/10; dysphagia; symptoms of a UTI; antibiotic treatment;
anticipated length of stay less than 1 week; regular drinkers of cranberry juice; presence of an in-dwelling
catheter; and terminal illness.
In light of a UK Committee on Safety of Medicines alert about a potential interaction between cranberry
juice and warfarin which emerged during the final 8 weeks of recruitment, warfarin was added as an exclusion
for that period only.
Interventions INTERVENTION
300 mL of cranberry juice.
CONTROL
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Characteristics of included studies (Continued )
Matching placebo beverage.
DURATION
6 months
Outcomes 1. Time to onset of first symptomatic UTI. This was defined as a culture positive urine growing a single
organism of > 10(4) cfu/mL urine specimen.
2. Adherence to beverage drinking, courses of antibiotics prescribed, and organisms responsible for UTIs.
Notes METHOD OF OBTAINING URINE SAMPLES
Clean catch.
DEFINITION OF BACTERIURIA
Only pure growths of >/= 10(4) cfu/mL were reported with an antibiotic sensitivity.
Allocation concealment A – Adequate
Study Schlager 1999
Methods Country: USA
Source of patients: NS
Method of allocation/randomisation: Pharmacy
Blinding: Double blind (participants and investigators)
Number of centres: One
Design: Cross-over
Power calculation: No
Number of patients randomised: 15
Number of patients analysed: 15
Losses to follow-up/withdrawals: None
Exclusions post randomisation: None
Intention-to-treat analysis: Yes
Source of funding: Grants from Spinal Cord Research Foundation and the Pendleton Pediatric Infectious
Disease Research Laboratory.
Participants INCLUSION CRITERIA
Neuropathic bladder and managed by clean intermittent catheterisation.
Lived at home, had normal findings on renal ultrasonography and voided cystourethrogram, and lived within
a 1 hour drive of the hospital.
Number: 15 children
Age: 2-18 years
EXCLUSION CRITERIA: NS
Interventions INTERVENTION
300 mL cranberry juice cocktail/day (30% cranberry concentrate).
CONTROL
Placebo beverage that looked and tasted similar but contained no cranberry juice.
DURATION
3 months cranberry juice, 3 months placebo.
Outcomes 1. Presence of bacteriuria.
2. Symptomatic UTI.
Notes METHOD OF OBTAINING URINE SAMPLE
CSU
DEFINITION OF SYMPTOMATIC UTI
Defined as bacteriuria with fever, abdominal pain, change in continence pattern, or change in colour or
odour of urine.
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Characteristics of included studies (Continued )
DEFINITION OF BACTERIURIA
>/= 100,000/mL
Allocation concealment A – Adequate
Study Stothers 2002
Methods Country: Canada
Source of participants: NS
Method of randomisation/allocation: Computer and sealed envelopes (see footnote 1).
Blinding: Double blind (participants and investigators)
Number of centres: One
Design: Placebo controlled
Power calculations: No
Number of patients randomised: 150
Number of patients analysed: 150
Losses to follow-up/withdrawals: 2 patients in the cranberry juice arm dropped out.
Exclusions post randomisation: None
Intention-to-treat analysis: yes (see footnote 1).
Source of funding: NS
Participants INCLUSION CRITERIA
At least two symptomatic, single-organism, culture positive UTIs in the previous calendar year, but were
currently free of UTI on urinalysis and culture.
Number: 150 sexually active women.
Age: 21-72 years
EXCLUSION CRITERIA
Neurogenic bladder dysfunction, insulin-dependent diabetes, immunosuppressive disease, steroid use, or
intermittent or indwelling catheterisation.
Interventions INTERVENTION 1
Placebo juice + cranberry tablets (1:30 parts concentrated juice, two times/day).
INTERVENTION 2
Cranberry juice 250 mL three times daily + placebo tablets.
CONTROL
Placebo juice (filtered water with food colouring + 20 mL pineapple juice) + placebo tablets.
DURATION
One year.
Outcomes 1. > 50% decrease in symptomatic UTI’s/year (symptoms + >/= 100,000 single organisms/mL).
2. > 50% decrease in annual antibiotic consumption.
3. Costs effectiveness of treatment.
Notes METHOD OF COLLECTING URINE SAMPLE
CSU
DEFINITION OF BACTERIURIA
Bacteria in the urine greater or equal to 100,000/mL.
Allocation concealment A – Adequate
Study Waites 2004
Methods Country: USA
Source of participants: Community residing men and women.
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Characteristics of included studies (Continued )
Method of allocation/randomisation: NS
Blinding: Double blind
Number of centres: One
Design: Parallel group
Power calculations: No
Number of patients randomised: 74
Number of patients analysed: 48
Losses to follow-up/withdrawals: 26
Exclusions post randomisation: None
Intention-to-treat analysis: No
Source of funding: NS, but CranBerry capsules were provided by Aim This Way, Cambridge, Massachusetts.
Participants INCLUSION CRITERIA
At least one year post spinal cord injury, age 16 years or older, neurogenic bladder managed by clean
intermittent catheterization or external collection device, no systemic antimicrobials or urinary acidifying
agents taken within 7 days, no current fever and chills suggestive of acute symptomatic UTI, and agreement
not to ingest and cranberry-containing products whilst participation in the clinical trial.
Baseline urine culture demonstrating at least 10(5) cfu/mL.
Number: 48 people.
Interventions INTERVENTION
2 g of concentrated cranberry juice in capsule form.
CONTROL
Placebo capsule.
DURATION
6 months.
Outcomes Baseline urinalysis and cultures were performed at the time of the initial clinic visit andmonthly for 6months.
Notes Microbiologic data were evaluated using analysis of variance with repeated measures.
METHOD OF OBTAINING URINE SAMPLE
CSU or clean catch.
DEFINITION OF BACTERIURIA
>/= 100,000/mL
Allocation concealment B – Unclear
Study Walker 1997
Methods Country: USA
Source of participants: NS
Method of randomisation/allocation: NS
Blinding: Double blind (participants and doctors)
Number of centres: One
Design: Placebo controlled, cross-over
Power calculation: No
Number of patients randomised: 19
Number of patients analysed: 10
Losses to follow-up/withdrawals: 9
Exclusions post randomisation: None
Intention-to-treat analysis: No
Source of funding: NS, but capsules provided by Solaray, Inc
Participants INCLUSION CRITERIA
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Non pregnant, sexually active women between the ages of 18 and 45 years with a recurrent UTI (4 UTIs
during the past year or at least one during the previous 3 months).
Number: 9 married, sexually active women.
Age: 28-44 years (median 37)
EXCLUSION CRITERIA: NS
Interventions INTERVENTION
Cranberry capsules containing 400 mg of cranberry solids (number/day not stated).
CONTROL
Placebo capsule.
DURATION
Each patient had 3 months of active treatment and 3 months placebo.
Outcomes 1. Symptomatic UTI.
Notes METHOD OF OBTAINING URINE SAMPLE: NS
DEFINITION OF SYMPTOMATIC UTI
Women notified the physician and then submitted a urine sample (method: NS).
To ensure a consistent entry point into the study, each participant was held in a queue until suffering a
symptomatic UTI.
Each subsequent UTI episode was treated with antibiotics.
Allocation concealment B – Unclear
cfu - colony forming units; NS - not stated
Footnote 1. Additional information provided by author(s).
Characteristics of excluded studies
Study Reason for exclusion
Jackson 1997 RCT of elderly people looking at the effect of cranberry juice on urinary acidity.
No relevant outcomes reported.
Schultz 1984 RCT, (placebo controlled) of eight subjects with multiple sclerosis.
Only randomised to 20 days of treatment. The inclusion criteria for this review was a minimum length of treatment
of one month. Furthermore, number of UTIs was not a primary outcome and only descriptively reported.
A D D I T I O N A L T A B L E S
Table 01. Characteristics of studies
Author Year N Country Setting Participants Intervention
Avorn 1994 192 USA Nursing homes Elderly women, mean age
78.5 years
300 mL cranberry
juice cocktail/day (30%
cranberry concentrate)
Haverkorn 1994 38 Netherlands Hospital Elderly men (9) and women
(29), mean age 81 years
30 mL cranberry juice/day
(concentration not
specified)
Foda 1995 40 Canada Hospital clinic Children with neuropathic 15 mL/kg cranberry
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Table 01. Characteristics of studies (Continued )
Author Year N Country Setting Participants Intervention
bladder requiring
clean intermittent
catheterisation, mean age
9.35 years
juice cocktail/day (30%
cranberry concentrate)
Walker 1997 19 USA Family practice Young women with
recurrent UTI, median age
37 years
Cranberry capsules (400
mg of cranberry solids)
Schlager 1999 15 USA Hospital clinic Children with neuropathic
bladder requiring
clean intermittent
catheterisation, aged 2-18
years
300 mL cranberry
juice cocktail/day (30%
cranberry concentrate)
Kontiokari 2001 150 Finland Student health service Young women (mean age
29-32 years) with previous
UTI
50 mL cranberry-
lingonberry juice five
days/week (7.5 g cranberry
concentrate)
Stothers 2002 150 Canada Unclear Women with recurrent UTI
(aged 21-72 years)
Cranberry juice (250 mL
three times/day) or one
concentrated cranberry
juice tablet twice daily
Linsenmeyer 2004 21 USA Urology rehabilitation
clinic
Spinal cord injury patients
with neuropathic bladders
Cranberry tablets (400 mg)
Waites 2004 48 USA Hospital clinic Spinal cord injury with
neuropathic bladder
Cranberry juice concentrate
(2 g)
McMurdo 2005 376 Scotland Hospital Elderly inpatients 300 mL cranberry juice
Table 02. Study design and quality of reporting
Author Design
Study
duration
Urine
collection Threshold
Other def-
initions Allocation
Loss to
follow-up Blinding
Intention-
to-treat
Avorn
1994
Parallel 6 months Voided = 10(8)/L Pyuria
(not
defined)
No (quasi-
RCT -
assigned
by ID or
phone
number)
71/192
(36.9%)
Partici-
pants, in-
vestigators
Unclear
Haverkorn
1994
Crossover 4 weeks Not stated = 10(8)/L No (quasi-
RCT by
date of
birth)
22/38
(57.9%)
Unclear Unclear
Foda 1995 Crossover 6 months Catheter = 10(8)/L Unclear 19/40
(47.5%)
Investiga-
tors
Unclear
Walker Crossover 3 months Not stated Not stated Symptoms Unclear 9/19 Partici- Unclear
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Table 02. Study design and quality of reporting (Continued )
Author Design
Study
duration
Urine
collection Threshold
Other def-
initions Allocation
Loss to
follow-up Blinding
Intention-
to-treat
1997 present
(not
defined)
(47.4%) pants, in-
vestigators
Schlager
1999
Crossover 3 months Catheter = 10(7)/L Symptoms
present
(defined)
Yes,
pharmacy
0/15 (0%) Partici-
pants, in-
vestigators
Yes
Kontiokari
2001
Parallel 6 months Voided = 10(8)/L Symptoms
present
(defined)
Yes, sealed
opaque
envelopes
13/150
(8.7%)
Unclear Yes
Stothers
2002
Parallel 12 months Voided = 10(8)/L Symptoms
present
(unde-
fined)
Yes, sealed
envelopes
2/150
(1.3%)
Partici-
pants, in-
vestigators
Yes
Linsen-
meyer
2004
Crossover 9 weeks Catheter
or voided
= 10(8)/L White
blood cell
count
Unclear Partici-
pants, in-
vestigators
Waites
2004
Parallel 6 months Catheter
or voided
= 10(8)/L Unclear Partici-
pants, in-
vestigators
No
McMurdo
2005
Parallel 6 months Voided = 10(4)/L Symptoms
present
(not
defined)
Yes, sealed
envelopes
Partici-
pants, in-
vestigators
Yes
Table 03. Asymptomatic UTIs (bacteraemia)
Study Pre crossover P value End of of study data P value Notes
Schlager 1999 Cranberries: 85/97;
placebo 33/55
Not stated Cranberries: 120/160
(75%); placebo 114/151
(75%)
Not stated
Havercorn 1994 Not stated Not stated Not stated p = 0.004 Actual number of people
in each group not stated.
Avorn 1994 N/A N/A Cranberries: 20/473 (4%)
of the urine samples;
placebo
Foda 1995 Not stated Not stated Cranberry: 27/112
months (24.1%); placebo:
34/117 months (29%)
Not stated Months with
positive/significant culture
but no UTI symptoms
Linsenmeyer 2003 Not stated Not stated Not stated Not stated The authors report that,
’We failed to find a
statistically significant
treatment effect for
21Cranberries for preventing urinary tract infections (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Table 03. Asymptomatic UTIs (bacteraemia) (Continued )
Study Pre crossover P value End of of study data P value Notes
the cranberry tablets
beyond the placebo effect
when evaluating urinary
bacterial count (t20=-
0.05,p=0.96), urinary
WBC (t20= 1.14, p=0.27),
or urinary bacterial and
WBC in combination
(t20=1.14,p=0.27
Table 04. Symptomatic UTIs
Study Pre-crossover P value End of trial data P value Notes
Schlager 1999 Not stated Not stated Cranberry: 3 UTIs in
2 children; placebo: 3
UTIs in 3 children
Not stated
Avorn 1994 Not applicable Not applicable Cranberry: 20/473
(4%); placebo: 37/498
(7%)
Not significant (p value
not stated)
Denominator unclear
Walker 1997 Not stated Not stated Cranberry: 6 UTIs;
placebo: 15 UTIs
p < 0.05 Whilst taking cranberry
capsules as opposed
to placebo, 7 of the
10 subjects exhibited
fewer UTIs, two subjects
exhibited the same
number of UTIs, and
one subject experienced
one more UTI.
Foda 1995 Not stated Not stated Cranberry: 19/112
months (17%); placebo:
20/117 months (17.1%)
Not stated Months with
positive/significant
culture and UTI
symptoms
Havercorn 1994 Not stated No details provided
A N A L Y S E S
Comparison 01. Cranberry products versus placebo/control
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 At least one symptomatic UTI 4 665 Relative Risk (Random) 95% CI 0.66 [0.47, 0.92]
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Beverages; Cross-Over Studies; ∗Phytotherapy; Randomized Controlled Trials; Sex Factors; Urinary Tract Infections [∗prevention &
control]; ∗Vaccinium macrocarpon
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Cranberry products versus placebo/control, Outcome 01 At least one
symptomatic UTI
Review: Cranberries for preventing urinary tract infections
Comparison: 01 Cranberry products versus placebo/control
Outcome: 01 At least one symptomatic UTI
Study Cranberry Control Relative Risk (Random) Weight Relative Risk (Random)
n/N n/N 95% CI (%) 95% CI
01 Women with recurrent UTIs
Kontiokari 2001 12/46 19/45 31.4 0.62 [ 0.34, 1.12 ]
Stothers 2002 19/100 16/50 33.9 0.59 [ 0.34, 1.05 ]
Subtotal (95% CI) 146 95 65.3 0.61 [ 0.40, 0.91 ]
Total events: 31 (Cranberry), 35 (Control)
Test for heterogeneity chi-square=0.01 df=1 p=0.92 I² =0.0%
Test for overall effect z=2.39 p=0.02
02 Elderly men and women
McMurdo 2005 7/187 14/189 14.2 0.51 [ 0.21, 1.22 ]
Subtotal (95% CI) 187 189 14.2 0.51 [ 0.21, 1.22 ]
Total events: 7 (Cranberry), 14 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=1.51 p=0.1
03 People with neuropathic bladders
Waites 2004 10/26 8/22 20.5 1.06 [ 0.51, 2.21 ]
Subtotal (95% CI) 26 22 20.5 1.06 [ 0.51, 2.21 ]
Total events: 10 (Cranberry), 8 (Control)
Test for heterogeneity: not applicable
Test for overall effect z=0.15 p=0.9
Total (95% CI) 359 306 100.0 0.66 [ 0.47, 0.92 ]
Total events: 48 (Cranberry), 57 (Control)
Test for heterogeneity chi-square=2.13 df=3 p=0.55 I² =0.0%
Test for overall effect z=2.43 p=0.01
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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